Our analysis and experimental findings highlight CNN3 as a key factor in cAML prognosis, with its knockdown improving outcomes in AML models, suggesting CNN3 as a potential therapeutic target for cAML. This evidence concerns the gene CNN3 and acute myeloid leukemia.